Last reviewed · How we verify
OCV-501
At a glance
| Generic name | OCV-501 |
|---|---|
| Sponsor | Otsuka Pharmaceutical Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Phase 2 Trial to Evaluate the Efficacy and Safety of OCV-501 in Elderly Patients With Acute Myeloid Leukemia (PHASE2)
- A Phase I Study of OCV-501 in Acute Myeloid Leukemia Patients (PHASE1)
- Study of OCV-501 in Patients With Acute Myeloid Leukemia (AML) (Extension From Study 311-10-001) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- OCV-501 CI brief — competitive landscape report
- OCV-501 updates RSS · CI watch RSS
- Otsuka Pharmaceutical Co., Ltd. portfolio CI